Inhibikase Says FDA Clears IND For IkT-001Pro To Treat Chronic Myelogenous Leukemia

RTTNews | 1118天前
Inhibikase Says FDA Clears IND For IkT-001Pro To Treat Chronic Myelogenous Leukemia

(RTTNews) - Pharmaceutical company Inhibikase Therapeutics, Inc. (IKT) announced Friday that the U.S. Food and Drug Administration (FDA) has reviewed its Investigational New Drug (IND) application for IkT-001Pro for the treatment of Chronic Myelogenous Leukemia (CML) and issued a Study May Procced (SMP) letter.

IkT-001Pro is a prodrug formulation of imatinib mesylate and has been developed to improve the safety of the first FDA-approved Abelson (Abl) kinase inhibitor, imatinib (marketed as Gleevec).

IkT-001Pro has the potential to be a safer alternative for patients and may improve the number of patients that reach and sustain major and/or complete cytogenetic responses in stable-phase CML.

In preclinical studies, IkT-001Pro was shown to be as much as 3.4 times safer than imatinib in non-human primates, reducing burdensome gastrointestinal side effects that occur following oral administration.

Imatinib delivered as IkT-001Pro was granted Orphan Drug Designation for stable-phase CML in September, 2018.

IkT-001Pro will be evaluated in a single ascending dose bioequivalence study and will enroll approximately 64 male and female healthy volunteers aged 25 to 55 who will receive IkT-001Pro at one of four doses.

For More Such Health News, visit rttnews.com

read more
European Economic News Preview: Bank Of England To Hold Rate

European Economic News Preview: Bank Of England To Hold Rate

The monetary policy announcement from the Bank of England is the top economic event due on Thursday. The BoE is widely expected to hold its benchmark bank rate at 4.00 percent after a quarter-point reduction in August. The bank had lowered the rate five times since August 2024 and took it to the lowest since early 2023.
RTTNews | 48分钟前
Australian Market Extends Early Losses In Mid-market

Australian Market Extends Early Losses In Mid-market

The Australian market is extending its early losses in mid-market moves on Thursday, adding to the losses in the previous session, following the mixed cues from Wall Street overnight. The benchmark S&P/ASX 200 is falling well below the 8,800 level, as markets digested a softer-than-expected domestic jobs report, with weakness across most sectors led by mining and energy stocks.
RTTNews | 2小时35分钟前
Asian Markets Trade Mostly Higher

Asian Markets Trade Mostly Higher

Asian stock markets are trading mostly higher on Thursday, following the mixed cues from Wall Street overnight, after the US Fed delivered a widely expected quarter point interest rates cut to 4.0 percent, citing a shift in the balance of risks. The latest projections from Fed officials also suggest they expect the central bank to lower rates two more times this year.
RTTNews | 2小时49分钟前
Sensex, Nifty Seen Higher At Open

Sensex, Nifty Seen Higher At Open

Indian shares look set to open on a positive note on Thursday, tracking mixed cues from global markets.
RTTNews | 3小时27分钟前
Japanese Market Notably Higher

Japanese Market Notably Higher

The Japanese market is trading notably higher on Thursday, reversing the losses in the previous session, following the mixed cues from Wall Street overnight. The Nikkei 225 is moving above the 45,000 mark, with gains across most sectors led by exporters and technology stocks.
RTTNews | 4小时18分钟前
Australian Market Modestly Lower

Australian Market Modestly Lower

The Australian market is trading modestly lower on Thursday, extending the losses in the previous session, following the mixed cues from Wall Street overnight. The benchmark S&P/ASX 200 is falling below the 8,800 level, with weakness across most sectors led by mining and energy stocks.
RTTNews | 4小时59分钟前